



PRESS RELEASE

## Kineta Scientist to Present Novel Antiviral Research Findings at International Conference

*Multiple, potent, small molecules found to target RIG-I innate immune pathway*

SEATTLE, WA, April, 20, 2010 – Kineta, Inc. today announced a lead scientist from the company will present the latest findings from its preclinical antiviral drug development program - agonists of the Retinoic Acid Inducible Gene I (RIG-I), to the International Conference for Antiviral Research (ICAR) in San Francisco. Research scientist, Kristin Bedard, Ph.D. will offer an oral presentation on the program during the afternoon session of the conference, Wednesday, April 28<sup>th</sup>, 2010.

Dr. Bedard will provide an overview of five drug-like small molecule agonists of the RIG-I innate immune pathway. Each of the molecules has demonstrated effective antiviral activity against one or both of the hepatitis C and influenza viruses. An abstract of the work will be published in the journal, *Antiviral Research*.

“We are very optimistic about the direction of our antiviral program and the scientific momentum achieved by Dr. Bedard. Her findings are the first to demonstrate small molecule antiviral agonists of the RIG-I pathway, a critical first step to developing a better antiviral drug,” said Chief Scientific Officer and Executive Vice President, Shawn P. Iadonato, Ph.D.

The prestigious ICAR forum provides an interdisciplinary view of cutting-edge antiviral drug research and development. More than 300 scientists are expected to attend the three-day conference.

Kineta’s goal with its RIG-I program is to develop a broad based antiviral drug with efficacy against multiple deadly viruses including: influenza, hepatitis C, West Nile virus and numerous other viral pathogens. The company is also developing vaccine adjuvants.

For more information on today’s announcement or to schedule interviews, contact Meg O’Conor, Director of Investor Relations and corporate communications, [moconor@kinetabio.com](mailto:moconor@kinetabio.com), 206-251- 8638.

#####

**Kineta, Inc.** is a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. Our world class scientists are pioneers in developing life-changing classes of drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, [www.Kinetabio.com](http://www.Kinetabio.com)